دورية أكاديمية
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
| العنوان: | Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial |
|---|---|
| المؤلفون: | Koshino, A, Neuen, BL, Oshima, M, Toyama, T, Hara, A, Arnott, C, Neal, B, Jardine, M, Badve, SV, Mahaffey, KW, Pollock, C, Hansen, MK, Wada, T, Heerspink, HJL |
| المصدر: | urn:ISSN:2468-0249 ; Kidney International Reports, 9, 2, 347-355 |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2024 |
| المجموعة: | UNSW Sydney (The University of New South Wales): UNSWorks |
| مصطلحات موضوعية: | Clinical Research, Clinical Trials and Supportive Activities, Hematology, Kidney Disease, Prevention, Diabetes, 2 Aetiology, 2.1 Biological and endogenous factors, Metabolic and endocrine, Renal and urogenital, 3 Good Health and Well Being, SGLT2 inhibitor, anemia, biomarker, cardiovascular, kidney, mortality |
| الوصف: | Introduction: Autoantibodies to erythropoietin receptor (anti-EPOR antibodies) have been identified in patients with various kidney diseases. However, data in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) is limited. We assessed the prevalence of anti-EPOR antibodies and their association with clinical outcomes in this population. Methods: The CREDENCE randomized patients with T2D and CKD to canagliflozin or placebo. Serum anti-EPOR antibodies, the exposure of interest, were measured using enzyme-linked immunosorbent assay. The primary outcome was doubling of serum creatinine, end-stage kidney disease, or death from kidney or cardiovascular (CV) causes. Secondary outcomes included CV and all-cause mortality. Multivariable Cox-regression models estimated associations between anti-EPOR antibodies and outcomes. The effects of canagliflozin on hemoglobin and hematocrit, stratified by the presence of anti-EPOR antibodies were assessed with a repeated measures mixed effects model. Results: Of 2600 participants with available biosamples, 191 (7.3%) were positive for anti-EPOR antibodies. Higher baseline anti-EPOR antibodies were associated with increased risk of primary outcome (hazard ratio [HR] per 1-SD increase = 1.12, 95% confidence interval [CI] = 1.01–1.24, P = 0.04), with CV death (HR = 1.27, 95% CI = 1.08–1.48, P < 0.01) and all-cause mortality (HR = 1.26, 95% CI = 1.11–1.43, P < 0.01). During follow-up, canagliflozin, compared to placebo, increased hemoglobin and hematocrit by 7.0 g/l (95% CI = 6.2–7.9) and 2.4% (2.2–2.7), respectively. These effects were consistent across patients with and without anti-EPOR antibodies (P-interaction = 0.24 and 0.36, respectively). Conclusion: In patients with T2D and CKD, anti-EPOR antibodies were associated with the composite kidney and CV outcome, as well as CV and all-cause mortality. Canagliflozin increased hemoglobin and hematocrit regardless of anti-EPOR antibodies. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | http://hdl.handle.net/1959.4/unsworks_85167Test; https://unsworks.unsw.edu.au/bitstreams/fd397001-8203-4fc5-9aaf-f2b8206f7c44/downloadTest; https://doi.org/10.1016/j.ekir.2023.11.024Test |
| DOI: | 10.1016/j.ekir.2023.11.024 |
| الإتاحة: | https://doi.org/10.1016/j.ekir.2023.11.024Test http://hdl.handle.net/1959.4/unsworks_85167Test https://unsworks.unsw.edu.au/bitstreams/fd397001-8203-4fc5-9aaf-f2b8206f7c44/downloadTest |
| حقوق: | open access ; https://purl.org/coar/access_right/c_abf2Test ; CC-BY ; https://creativecommons.org/licenses/by/4.0Test/ ; CC BY ; free_to_read |
| رقم الانضمام: | edsbas.8DA8CFD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ekir.2023.11.024 |
|---|